Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target dysfunctional metabolic pathways to treat diseases including NASH and specific cancers. The company is advancing TVB-2640, an oral, first-in-class fatty acid synthase (FASN) inhibitor, and plans a Phase 2b trial evaluating histological endpoints. In its Phase 2 randomized placebo-controlled FASCINATE-1 trial, TVB-2640 significantly decreased liver fat and improved serum biomarkers of liver injury, fibrosis and inflammation in NASH patients. Sagimet also intends to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021. The company is led by CEO George Kemble, PhD, and is based in San Mateo, California. It is using recent financing to advance its lead program and explore additional indications. Sagimet Biosciences is a San Mateo, Calif.-based clinical-stage biopharmaceutical company led by George Kemble, PhD, CEO and CSO. The company focuses on developing novel therapeutics that target dysfunctional metabolic pathways to treat NASH and specific cancers. Its lead candidate is TVB-2640, an orally bioavailable, first-in-class FASN inhibitor targeting de novo lipogenesis (DNL) to reduce excess liver fat in NASH patients. Sagimet will use the recently raised funds to continue advancing TVB-2640 through clinical development. The company has completed a second tranche of its Series E financing, bringing the round to $25M in total. Prior funding activity in the Series E included an initial $18M funded in February 2019. No revenue or user metrics were reported in the article. 3-V Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target dysfunctional metabolic pathways, including the FASN inhibitor TVB-2640 (ASC40). TVB-2640 is described as a first-in-class, orally bioavailable FASN inhibitor and a Phase 2-ready drug candidate for non-alcoholic steatohepatitis (NASH). The company plans Phase 2 multi-center trials of TVB-2640 in the United States and China and will evaluate the drug's impact on liver fat using advanced imaging techniques. In conjunction with the financing, 3-V Biosciences granted an exclusive license to Ascletis to develop, manufacture and commercialize ASC40 (TVB-2640) in Greater China. Under that license 3-V Biosciences is eligible to receive development and commercial milestones as well as tiered royalties on future net sales. Financially, 3-V Biosciences raised US$18 million in a Series E financing and has commitments for an additional US$7 million in a subsequent financing to support continued development of TVB-2640. 3-V Biosciences is a Menlo Park-based biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. Its lead candidate, TVB-2640, is an oral proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors. The company is advancing oncology clinical trials both as monotherapy and in combination with cytotoxic agents, including phase IB expansion cohorts. It also has a second program in preclinical and IND-enabling stages with plans to file for regulatory (IND or CT) clearance in 2015. 3-V is led by CEO Merdad Parsey, M.D., Ph.D. Financially, the company closed a $28.5M Series D to support these oncology programs. 3-V Biosciences discovers and develops therapeutics that target key pathways in oncology and infectious disease. Its lead oncology candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. The company is also evaluating antiviral therapeutic candidates for respiratory syncytial virus (RSV), herpes simplex virus (HSV) and hepatitis C virus (HCV). 3-V intends to use the funds from its financing to advance its lead oncology candidate into a Phase 1 clinical trial and to support ongoing preclinical studies of multiple virology leads generated by its integrated drug discovery process. The company completed a $20m Series C financing, and backers included existing investors Kleiner Perkins Caufield & Byers and New Enterprise Associates. Merdad Parsey, M.D., Ph.D., serves as Chief Executive Officer.

Total raised

$174M

Funding rounds

6

Latest round

Equity

Latest activity

Feb 2021